A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

Genetically modified organisms, also known as GMOs, have been a hot topic of conversation among researchers, producers, ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Our new but simple method is far more effective and can now be applied to a much wider range of plant species than our ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

Tom Brady's dog is a clone of a "beloved" pet that died, the seven-time Super Bowl champion revealed on Tuesday.

Cathie Wood's Ark Invest sold shares of five biotech and healthcare companies in recent trades. She also offloaded over 1.1 ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.